A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 291 participants.

Also called NCT04591626

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 291 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04591626
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04591626. Randomized; double masking; primary purpose treatment. Start 2020-12-07 (actual); primary completion 2022-04-28 (actual). Results posted on 2023-05-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
Acronym
AWARD-CHN3
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Dulaglutide
Intervention (Drug)
Placebo
Intervention (Drug)
Insulin Glargine
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct04591626
Content hash
95423a741bedd86af0dae43f25482597832705eb033357cfe0765eef9303cde6